|
|
||||||||
Inflammation and Fibrosis |
Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
Correspondence to: T.J. Tsai, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan. paul{at}ha.mc.ntu.edu.tw
Peritoneal fibrosis (PF) is an important issue in peritoneal dialysis
(PD) because it remains one of the leading causes of patient drop-out from PD.
In this review, we focus on in vitro approaches to the pathogenesis
and therapeutic potential of PF and on associated clinical implications.
Representative Asian studies, initiated since mid-1990s, that have
investigated matrix accumulation in peritoneal tissue possibly leading to PF
in the PD population will be highlighted as examples to learn how to apply
this research tool. As compared with data from well-designed clinical trials,
observations from in vitro models may be far from becoming solid
evidence; however, they do cast new light on options for investigations into
therapeutic pharmaceuticals.
KEY WORDS: In vitro study; peritoneal fibrosis; mesothelial cell; fibroblast; cytokine; tamoxifen.
This article has been cited by other articles:
![]() |
K.-Y. Hung, J.-W. Huang, C.-K. Chiang, and T.-J. Tsai Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3831 - 3840. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |